JERUSALEM (Reuters) – Israeli Cytoryain, which uses artificial intelligence (AI) to develop disease models, said on Wednesday it had raised $80 million in a private funding round.
CytoReason said participation in the investment round included Nvidia, Pfizer, Thermo Fisher and venture capital investor OurCrowd.
The company said it aims to expand the model's scope to additional indications and to gather more proprietary molecular and clinical data.
The company plans to open an office in Cambridge, Massachusetts later this year.
In 2022, Pfizer expanded its collaboration with CytoReason, investing $20 million that could reach $110 million by 2027.
“The rapid expansion of new technologies such as satellites
“This artificial intelligence has great potential to really transform the promise of human health,” said Mikael Dolsteyn, Pfizer's chief scientific officer.
“Our collaboration with CytoReason will leverage their cutting-edge immunology multi-omics platform to enhance Pfizer's own research and development capabilities and generate valuable insights into drug development pathways for patients.”
CytoReason said six of the world's top 10 pharmaceutical companies use its technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism and other therapeutic areas.
Areas using AI platforms for computational disease modeling.
(Reporting by Stephen Shea; Editing by Jason Neely)
